(Q34544256)

English

Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

phase I clinical trial

0 references

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

Enriqueta Felip

object named as

Enriqueta Felip

2

0 references

Hossein Borghaei

4

object named as

Hossein Borghaei

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

author name string

Teresa Moran

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Vicki Keedy

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Frances A Shepherd

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Amelia Insa

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Holly Brown

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Timothy Fitzgerald

8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Sriram Sathyanarayanan

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

John F Reilly

10

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

David Mauro

11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Karl Hsu

12

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Li Yan

13

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

David H Johnson

14

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

publication date

7 November 2014

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Experimental Hematology & Oncology

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

copyright license

Creative Commons Attribution 4.0 International

7 November 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237770

7 July 2018

Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237770

7 July 2018

A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237770

7 July 2018

Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237770

7 July 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237770

7 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4237770

7 July 2018

Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.

1 reference

https://api.crossref.org/works/10.1186%2F2162-3619-3-26

21 January 2018

High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients.

1 reference

https://api.crossref.org/works/10.1186%2F2162-3619-3-26

21 January 2018

Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.

1 reference

https://api.crossref.org/works/10.1186%2F2162-3619-3-26

21 January 2018

Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1186%2F2162-3619-3-26

21 January 2018

Insulin-like growth factor-II as a prognostic factor in pulmonary adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25414803

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibody alpha IR-3 inhibits non-small cell lung cancer growth in vitro and in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/25414803

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/2162-3619-3-26

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34544256&oldid=2196760563"